{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:55:02Z","timestamp":1794246902207,"version":"4.9.0"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,2,3]]},"abstract":"\n Importance<\/jats:title>\n Obesity is a chronic, relapsing disease affecting over 1 billion people worldwide, driving substantial morbidity, mortality, and economic burden. Glucagon-like peptide-1 therapies (GLP-1 therapies) provide clinically meaningful weight loss and broad metabolic benefits. In response to Member State requests, the World Health Organization (WHO) has issued guidelines for adults living with obesity.<\/jats:p>\n <\/jats:sec>\n \n Observations<\/jats:title>\n \n The guidelines recognize obesity as a chronic, relapsing disease requiring lifelong care and emphasize early diagnosis and integrated, person-centered approaches combining behavioral, medical, surgical, and other interventions alongside prevention and management of comorbidities. WHO recommends long-term GLP-1 therapies combined with intensive behavioral therapy to maximize and sustain benefits. Both recommendations were graded\n conditional<\/jats:italic>\n , reflecting that GLP-1 therapies\u2014with or without behavioral therapy\u2014are effective, but limited long-term data, cost, system readiness, equity, variability in patient priorities, and context-specific feasibility remain considerations. Implementation of these guidelines depends on equitable access to affordable therapies, health system preparedness, and most importantly assurance that care is person-centered, nondiscriminatory, and universally accessible. Given the time required to implement these measures, a priority is a transparent, equitable, evidence-based framework to identify those at highest need while allowing incremental expansion of eligibility as access, capacity, and readiness evolve; this will be the next focus of the WHO guideline.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Medication alone cannot solve the global obesity burden. The availability of GLP-1 therapies should galvanize the global community to build a fair, integrated, and sustainable obesity ecosystem. Countries must ensure equitable access not only to comprehensive disease management, but also to health promotion and prevention policies and interventions targeting the general population and those at high risk.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2025.24288","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:30:28Z","timestamp":1764599428000},"page":"434","source":"Crossref","is-referenced-by-count":167,"title":["World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults"],"prefix":"10.1001","volume":"335","author":[{"given":"Francesca","family":"Celletti","sequence":"first","affiliation":[{"name":"Senior Advisor, Obesity, Department of Nutrition and Food Safety, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Farrar","sequence":"additional","affiliation":[{"name":"Assistant Director General, Health Promotion, Prevention, and Care, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz","family":"De Regil","sequence":"additional","affiliation":[{"name":"Director, Department of Nutrition and Food Safety, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10431","key":"jsc250014r2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.","volume":"403","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"jsc250014r10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015092.pub2","article-title":"Semaglutide for adults living with obesity.","volume":"10","author":"Bracchiglione","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"jsc250014r11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD016017","article-title":"Liraglutide for adults living with obesity.","volume":"10","author":"Meza","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"jsc250014r12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD016018","article-title":"Tirzepatide for adults living with obesity.","volume":"10","author":"Franco","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"jsc250014r13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity.","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"10456","key":"jsc250014r14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"issue":"14","key":"jsc250014r15","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jama.2025.14092","article-title":"Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction.","volume":"334","author":"Kr\u00fcger","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"jsc250014r16","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists.","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"issue":"12","key":"jsc250014r17","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"jsc250014r18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s13098-025-01888-1","article-title":"GLP-1 receptor agonists in Parkinson\u2019s disease: an updated comprehensive systematic review with meta-analysis.","volume":"17","author":"Helal","year":"2025","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"jsc250014r19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity?","volume":"49","author":"Melson","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"jsc250014r27","doi-asserted-by":"publisher","first-page":"q1645","DOI":"10.1136\/bmj.q1645","article-title":"GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment.","volume":"386","author":"Mahase","year":"2024","journal-title":"BMJ"},{"issue":"18","key":"jsc250014r29","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment.","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"key":"jsc250014r8","author":"World Health Organization"},{"key":"jsc250014r9","author":"US Food and Drug Administration","year":"2025"},{"key":"jsc250014r1","unstructured":"World Health Organization. ICD-11 for Mortality and Morbidity Statistics: 5B81 Obesity. Accessed November 19, 2025.https:\/\/icd.who.int\/browse\/2024-01\/mms\/en#149403041"},{"key":"jsc250014r3","unstructured":"World Health Organization. Obesity and overweight fact sheet. May 7, 2025. Accessed November 13, 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"key":"jsc250014r4","unstructured":"World Obesity Federation. World Obesity Atlas 2025. March 2025. Accessed November 19, 2025. https:\/\/data.worldobesity.org\/publications\/world-obesity-atlas-2025-v7.pdf"},{"key":"jsc250014r5","unstructured":"US Food and Drug Administration. FDA approves weight management drug for patients aged 12 and older. December 4, 2020. Accessed November 21, 2025. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-weight-management-drug-patients-aged-12-and-older?"},{"key":"jsc250014r6","unstructured":"US Food and Drug Administration. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. March 8, 2024. Accessed November 21, 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or"},{"key":"jsc250014r7","unstructured":"US Food and Drug Administration. FDA approves new medication for chronic weight management. November 8, 2023. Accessed November 21, 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-medication-chronic-weight-management?"},{"key":"jsc250014r20","unstructured":"GLP-1 agonists drug pipeline analysis market report 2025. GlobeNewswire. July 14, 2025. Accessed November 17, 2025. https:\/\/www.globenewswire.com\/news-release\/2025\/07\/14\/3114579\/28124\/en\/GLP-1-Agonists-Drug-Pipeline-Analysis-Market-Report-2025-Next-generation-GLP-1-Agonists-Pave-the-Way-for-Diabetes-and-Obesity-Management.html"},{"key":"jsc250014r21","unstructured":"US Food and Drug Administration. Guideline document. The extent of population exposure to assess clinical safety: for drugs intended for long-term treatment of non-life-threatening conditions. March 1995. Accessed November 20, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e1a-extent-population-exposure-assess-clinical-safety-drugs-intended-long-term-treatment-non-life"},{"key":"jsc250014r22","unstructured":"A study of LY3298176 (Tirzepatide) for the maintenance of body weight reduction in participants who have obesity or overweight with weight-related comorbidities. ClinicalTrials.gov identifier: NCT06047548. Updated April 18, 2025. Accessed November 20, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06047548"},{"key":"jsc250014r23","unstructured":"World Health Organization. WHO Handbook for Guideline Development, 2nd ed. December 18, 2014. Accessed November 19, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789241548960"},{"key":"jsc250014r24","unstructured":"World Health Organization. The selection and use of essential medicines, 2025. WHO Model List of Essential Medicine, 24th list. 2025. Accessed November 19, 2025. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/17642505-ecd3-4940-a691-4f1dfa0d835a\/content"},{"key":"jsc250014r25","unstructured":"World Health Organization. Health service delivery framework for prevention and management of obesity. May 13, 2023. Accessed November 20, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240073234?"},{"key":"jsc250014r26","unstructured":"Grand View Research. GLP-1 receptor agonist market report 2024\u20132030. Grand View Research; 2024. Accessed November 13, 2025. https:\/\/www.grandviewresearch.com\/industry-analysis\/glp-1-receptor-agonist-market"},{"key":"jsc250014r28","unstructured":"Goldman Sachs. The anti-obesity drug market may prove smaller than expected. May 22, 2025. Accessed November 21, 2025. https:\/\/www.goldmansachs.com\/insights\/articles\/the-anti-obesity-drug-market-may-prove-smaller-than-expected"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2842199\/jama_celletti_2025_sc_250014_1769111434.84472.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:00:48Z","timestamp":1770134448000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2842199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,2,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.24288","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}